LOUISVILLE, Ky. and LONDON, April 20, 2017 /PRNewswire/ -- NX Prenatal Inc. ("NX Prenatal") today announced that its innovative technology would be presented at an upcoming conference in London, at the invitation of a Preterm Birth Working Group organized by the International Federation of Gynecology and Obstetrics (FIGO) and the March of Dimes (MOD).
The FIGO/MOD Working Group consists of an international panel of experts exploring the role biomarkers could play in predicting preterm birth and other adverse pregnancy outcomes, and plans to make recommendations for the global obstetrical community. The closed meeting will take place in advance of the 1st World Congress on the Maternal Fetal and Neonatal Medicine being held this month.
NX Prenatal is focused on the development and launch of a novel exosome-based blood test designed to stratify the risk of preterm birth in women as early as 10-12 weeks of pregnancy to provide physicians with a new decision support tool. Dr. Thomas McElrath, who has served as Principle Investigator for NX Prenatal's recent clinical studies, will present to the FIGO/MOD group. Dr. McElrath is Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and an attending physician at Brigham & Women's Hospital where he specializes in Maternal & Fetal Medicine with a focus on the prevention of spontaneous preterm birth. Dr. McElrath manages the Preterm Birth Clinic at Brigham and Women's Hospital. He actively publishes on the biomarker epidemiology and classification of preterm birth and the interaction of environmental conditions and exposures with the risk of preterm birth.
Gail Page, NX Prenatal's Executive Chairperson, added, "Preterm birth is a global problem, and the FIGO and March of Dimes organizations are well-positioned to gather resources, raise awareness and support focused research utilizing novel approaches to support the prevention of preterm birth."
About NX Prenatal
NX Prenatal Inc. is a private, US-based molecular diagnostics company. The company's NeXosome® Preterm Birth Risk Assay is positioned to be an enabling, early warning system for pregnancies that may result in spontaneous preterm birth. Using its proprietary NeXosome Platform, NX Prenatal has demonstrated the potential utility of a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. This technology exploits biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal cells and tissues.
SOURCE NX Prenatal Inc.